Hepatitis C genotype 6: A concise review and response-guided therapy proposal

Table 2 Treatment outcomes of hepatitis C virus genotype 6 (compared to other genotypes)

Ref.	Design/treatment	Genotype	n	SVR	P value1
Dev et al[36]	Retrospective IFN + RBV 52 wk	6	33	82.5%	NR
		1	17	61.9%
Hui et al[37]	Prospective IFN + RBV 52 wk	6	16	62.5%	0.04
		1	24	29.2%
Cheng et al[43]	Retrospective PEG-IFN + RBV (duration not reported)	6	13	69.2%	0.026
		1	61	32.8%
		2	18	77.8%
Fung et al[38]	Prospective PEG-IFN + RBV 52 wk	6	21	85.7%	0.019
		1	21	52.4%
Nguyen et al[40]	Retrospective PEG-IFN + RBV (48 wk for genotype 1 and 6; 24 wk for genotype 2/3)	6	34	74.0%	0.016
		1	70	49.0%
		2/3	63	75.0%
Seto et al[30]	Retrospective IFN/PEG-IFN + RBV 52 wkIFN/PEG-IFN + RBV 52 wk	6	26	92.3%	NR
		1	21	42.9%
Tsang et al[41]	Retrospective PEG-IFN + RBV 48 wk	6	70	75.7%	NR
		1	70	57.1%
Zhou et al[42]	Retrospective PEG-IFN + RBV (48 wk for genotype 1b; 24 wk for genotype 2/3 and 6)	6	22	81.8%	0.068
		1b	39	59.0%
		2/3	42	83.3%
Tangkijvanich et al[48]	Prospective PEG-IFN + RBV (RGT2 for genotype 6; 48 wk for genotype 1; 24 wk for genotype 3)	6	34	76.5%	0.309
		1	16	62.5%
		3	16	81.3%

¹P value between genotype 6 vs genotype 1;

²Response-guided therapy (RGT) define as 24 wk for patients with rapid virological response and 48 wk for those without. PEG-IFN: Pegylated interferon; RBV: Ribavirin; SVR: Sustained virological response.